

Wisconsin



Wisconsin - AB 1058

Sponsor: Representative Shae Sortwell (R)

Actions: 02/17/2022 Introduced; Referred to Assembly Committee on Health

Summary: Summary for 2/17/2022 Version

This measure prohibits health care entities and credentialing boards from discriminating against health care providers who order innovative or novel therapies, as well as from interfering with a provider informing a patient of such therapies as long as certain conditions are met.

This measure prohibits a health care entity or credentialing board from discriminating against a health care provider for ordering an innovative or novel therapy so long as it is ordered based on the assessment of the provider and clinical data; the patient is informed of reasonable alternatives; and, if the therapy is a drug, device, or biological product, it is approved by the FDA. The health care entity or credentialing board also cannot interfere with a provider informing a patient about innovative novel therapies.

This measure is effective the day after publication.

Bill Links [2/17/2022 Version](#)



Wisconsin - AB 745

Sponsor: Representative Lisa Subeck (D)

Actions: 02/16/2022 Hearing Held
12/07/2021 Introduced; Referred to Assembly Health Committee

Summary: Summary for 12/07/2021

This measure prohibits insurers, pharmacy benefit managers, and utilization review organizations from requiring a step therapy protocol for certain drugs used to treat metastatic cancer and cancer-associated conditions.

This measure is applicable to insurers and pharmacy benefit managers.

This measure defines “cancer-associated condition” as any symptom or side effect that is associated with metastatic cancer or the treatment of metastatic cancer and that, in the judgment of a healthcare provider, further jeopardizes the health of a patient if left untreated.

This measure defines “metastatic cancer” as cancer that has spread from the primary or original site of cancer to nearby tissues, lymph nodes, or other areas or parts of the body.

This measure prohibits insurers, pharmacy benefit managers, or utilization review organizations from requiring a step therapy protocol for a drug prescribed for metastatic cancer or cancer-associated conditions. The drug use must be FDA approved, consistent with best practices for the specific condition, and supported by peer-reviewed, evidence-based research.

This measure does not list an effective date.

Bill Links [12/7/2021 Version](#)



Wisconsin - SB 716

Sponsor: Senator Janis Ringhand (D)

Actions: 11/19/2021 Introduced; Referred to Senate Insurance, Licensing, and Forestry Committee

Summary: Summary of 11/19/2021 Version

This measure will prohibit any health insurer, pharmacy benefit manager, or utilization review organization from requiring a step therapy protocol for drugs prescribed to treat metastatic cancer.

This measure is applicable to health insurers, pharmacy benefit managers, or utilization review organizations.

In this measure, an insurer, PBM, or utilization review organization will not require a step therapy protocol for a drug that is prescribed for metastatic cancer or a cancer-associated condition that is approved by the FDA, consistent with best practices for metastatic cancer treatment, and supported by peer-reviewed publications.

“Cancer-associated condition” means any symptom or side effect that is associated with metastatic cancer or the treatment of metastatic cancer and that, in the judgment of a health care provider, further jeopardizes the health of a patient, if left untreated.

This measure does not provide an effective date.

Bill Links [11/19/2021 Version](#)



Wisconsin - SB 982

Sponsor: Senator Duey Stroebel (R)

Actions: 02/17/2022 Introduced; Referred to Committee on Insurance, Licensing and Forestry Committee

Summary: Summary for 2/17/2022 Version

This measure prevents health care entities and credentialing boards from retaliating and discriminating against health care providers and restricting health care providers from informing a patient of an innovative therapy that would be beneficial to them

This measure prevents health care entities and credentialing boards from retaliating and discriminating against a health care provider for ordering an innovative or novel therapy. This measure prevents health care entities and credentialing boards from restricting any health care provider from informing a patient of an innovative or novel therapy that may benefit the patient.

This measure takes effect the day after enactment.

Bill Links [2/17/2022 Version](#)